Verastem Oncology
117 Kendrick Street
Suite 500
Needham
MA
02494
United States
Tel: (718) 292-4200
Website: http://www.verastem.com/
Email: info@verastem.com
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a clinical-stage biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.
Our team is anchored by core values of character, urgency, respect and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence. At Verastem, we believe that empowering employees is what makes them truly care about the important work they do.
Founded: 2010
349 articles with Verastem Oncology
-
Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference
5/25/2021
Verastem, Inc., a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced that the Company will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET.
-
Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
5/24/2021
Results of Early Trial Demonstrate 70% Overall Response Rate (ORR) in Patients with KRAS Mutant Tumors, 44% ORR in KRAS Wild-Type Tumors and 52% ORR in All Evaluable Patients with a Favorable Safety Profile
-
Verastem Oncology Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
5/11/2021
Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported financial results for the three months ended March 31, 2021, highlighted recent progress and outlined key corporate objectives.
-
Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results, Clinical Updates and Guidance for Key Milestones in 2021 and 1H 2022
3/18/2021
Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported financial results for the three months and full year ending December 31, 2020, and highlighted its key corporate objectives for 2021 and early 2022.
-
Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences Conference
3/2/2021
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will participate in the virtual H.C. Wainwright Global Life Sciences Conference. The fireside chat will be made available for on-demand listening beginning Tuesday, March 9, 2021 at 7:00 a.m. EST.
-
Frank Neumann, M.D., Ph.D., to Depart Verastem Oncology
1/20/2021
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the departure of the Company’s Chief Medical Officer, Frank Neumann, M.D., Ph.D., effective immediately.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 07, 2021
1/7/2021
Verastem, Inc., a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced the grant of options to purchase 86,250 shares of its common stock and the grant of 43,125 restricted stock units to five new employees.
-
Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer
12/15/2020
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, alone and in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC).
-
Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
11/30/2020
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, and defactinib
-
Verastem Oncology Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
11/9/2020
Announced Positive Updated Data from Ongoing Investigator-Initiated Phase 1/2 FRAME Study Evaluating VS-6766 and Defactinib Combination in Patients with Low-Grade Serous Ovarian Cancer
-
Verastem Oncology Announces New Data Published in The Lancet Oncology Supports Potential of VS-6766 as Treatment for RAS Mutant Tumors
10/28/2020
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced new data have been published today in The Lancet Oncology.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 06, 2020
10/6/2020
Verastem, Inc., a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced the grant of options to purchase 39,000 shares of its common stock to three new employees and the grant of 22,500 restricted stock units to two of the three new employees.
-
Verastem Oncology Announces Closing of COPIKTRA® (duvelisib) Sale to Secura Bio
9/30/2020
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer,
-
Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit
9/16/2020
Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2 nd Annual RAS-Targeted Drug Development Summit Preliminary Data on VS-6766 and Defactinib Combination Continues to Show Encouraging Response Rates, Durability and a Favorable Safety Profile in KRAS Mutant Low-Grade Serous Ovarian Cancer in Investigator-Initiated Trial New Preclinical Data Demonstrating Synergy and Tumor Regression with G12C Inhibitors in Combinatio
-
Verastem Oncology Announces Investor Conference Call to Discuss Updated Clinical Data in Low-Grade Serous Ovarian Cancer from Phase 1/2 FRAME Study
9/14/2020
New Results Evaluating Combination of VS-6766 and Defactinib to be Presented at the 2 nd Annual RAS-Targeted Drug Development Summit Management to Host Investor Conference Call and Webcast on Wednesday, September 16 at 8:00 AM ET BOSTON--( BUSINESS WIRE )-- Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that managem
-
Verastem Oncology to Present at Upcoming Investor Conferences - Sep 10, 2020
9/10/2020
Verastem, Inc., a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, announced that management will present virtually at the following upcoming investor conferences
-
Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors
8/10/2020
Verastem Will Receive $70 Million Up-Front with Total Deal Value Up to $311 Million, Plus Double-Digit Sales Royalties Upon Closing, Verastem’s Current Programs Will Be Funded Until At Least 2024 to Develop VS-6766 and Defactinib in Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Phase 2 Registration-Directed Trials Expected to Commence by Year End 2020 in Both Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Smal
-
Verastem Oncology Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
8/10/2020
Announced Path Forward for VS-6766 and Defactinib Combination Following Meeting with FDA Phase 2 Registration-Directed Trials Expected to Commence by Year End 2020 in Both Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Company Monetizes COPIKTRA ® (duvelisib) Providing Cash Runway Until at Least 2024 BOSTON--( BUSINESS WIRE )-- Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutic
-
Boston-based Verastem signed a definitive deal to sell its global commercial and development rights to Copiktra (duvelisib) to Henderson, Nevada and San Diego-based Secura Bio.
-
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 06, 2020
7/6/2020
Verastem, Inc., a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, announced the grant of options to purchase 20,000 shares of its common stock to two new employees.